Preparation of songorine nano-liposome and application of songorine nano-liposome in inhalation treatment of acute lung injury

By preparing phospholiposomes, the Song Guoling was encapsulated in a nanocarrier, and the problem of its insoluble in water and chemical properties was solved, targeted lung therapy was achieved, and the symptoms and biocompatibility of acute lung injury were significantly improved.

CN118948771AActive Publication Date: 2024-11-15GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411160761.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-15
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

In the prior art, Song Guoling is difficult to dissolve in water and has unstable chemical properties, which limits its application in the treatment of acute lung injury, especially its targeting and bioavailability in the body.

Method used

Songguoling nanoliposomes prepared using phospholipids, cholesterol and DSPE-mPEG2000 materials, improve the water solubility of the drug and lung targeting through thin-film hydration-ultrasonic dispersion method, forming a nanocarrier with high encapsulation rate.

Benefits of technology

It improves the water solubility and biocompatibility of Song Guoling, achieves targeted delivery to the lungs, reduces the level of inflammatory factors, significantly improves lung structural damage, and significantly better than the therapeutic effect of free drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0005006335960000011
    Figure HDA0005006335960000011
  • Figure HDA0005006335960000012
    Figure HDA0005006335960000012
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to preparation of songorine nano-liposome and application of songorine nano-liposome in inhalation treatment of acute lung injury. The songorine nano-liposome provided by the invention has good water solubility, biological safety and compatibility, and can act on the lung in a targeting manner after entering a living body, so that the expression level of inflammatory factors such as IL-6, IL-1beta and TNF-alpha is reduced, and inflammation is relieved; meanwhile, the expression levels of proteins such as ZO-1, VE-Cadherin and Claudin5 can be improved, and the injury of lung barriers can be relieved. Therefore, the songorine nano-liposome provided by the invention can be used for preparing the medicine for treating the acute lung injury, and the treatment effect of the songorine nano-liposome is obviously superior to that of a free songorine monomer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations and relates to the preparation of Songguoling nanoliposomes and their application in inhalation treatment of acute lung injury. Background Art

[0002] Acute lung injury (ALI) is the most serious manifestation of acute respiratory distress syndrome, characterized by severe inflammatory response, severe tissue damage, and high mortality rate. The current treatment strategies for ALI patients are mainly mechanical ventilation and anti-inflammatory drug therapy. An epidemiological survey in 2021 showed that among 1,909 patients with new coronavirus infection who were invasively ventilated, 1,672 (86.7%) developed acute respiratory distress syndrome, and the patient mortality rate was as high as 57.7%. Although mechanical ventilation can relieve symptoms to a certain extent, the patient mortality rate is still high; the most commonly used anti-inflammatory drug, glucocorticoids, can effectively reduce inflammation, but they often suppress the body's immune system and cause a series of side effects. Therefore, exploring new drugs and developing more reasonable and efficient treatment measures are of great significance for the treatment of ALI.

[0003] With the deepening of research on the effective ingredients and mechanisms of traditional Chinese medicine, many traditional Chinese medicine compounds have been found to have good pharmacological activity in recent years, but most natural compounds are poorly soluble in water, which limits their application. In order to improve the water solubility and bioavailability of compounds and better exert their clinical effectiveness, it is urgent to develop a nano-encapsulation carrier that can enhance the efficacy of compounds and has high stability. Terpenes are common fat-soluble and insoluble components that are poorly soluble in water and easily soluble in fat-soluble solvents such as petroleum ether, benzene, chloroform, and ethanol.

[0004] Songorine (Son) is a diterpene alkaloid isolated from the traditional Chinese medicine Aconitum. Studies have shown that it is a GABAA receptor antagonist in the rat brain and has anti-cancer, anti-arrhythmic and anti-inflammatory activities. However, because its molecular structure contains reaction substrates suitable for phenolase catalysis, the chemical properties of songorine are extremely unstable and it is easily oxidized by heat and light. Summary of the invention

[0005] The purpose of the present invention is to provide the preparation of Songguoling nanoliposomes and the application of inhalation in the treatment of acute lung injury, so as to solve the problems existing in the prior art.

[0006] According to one aspect of the present invention, a songguoling nanoliposome is provided, comprising a core material and a membrane material, wherein the core material is songguoling, and the membrane material is mainly prepared from phospholipids, cholesterol and DSPE-mPEG2000 (polyethylene glycol monomethyl ether-2000-dioctadecylphosphatidylethanolamine, CAS147867-65-0); the molar ratio of songguoling, phospholipids, cholesterol and DSPE-mPEG2000 is (10-18): (75-80): (18-22): 3, and the encapsulation efficiency of the songguoling nanoliposome is 75.03%±0.5%.

[0007] The Songguoling nanoliposomes provided by the present invention have good water solubility, which solves the problem that Songguoling is difficult to dissolve in water and has unstable chemical properties, and is therefore difficult to be applied in actual treatment. The phospholipid components in the liposomes give the liposomes good lung targeting, so that the liposomes can be targeted and transported to and act on the lungs after entering the body, reducing the levels of inflammatory factors such as TNF-α, IL-6, IL-1β in lung tissue, improving the damage to the normal structure of the lungs and their barriers, and increasing the permeability of the lungs. Therefore, it can be used to treat acute lung injury, and the therapeutic effect is significantly better than that of free Songguoling monomers. The Songguoling nanoliposomes provided by the present invention also have good biosafety and compatibility.

[0008] It should be noted that the molar ratio of DPPC (dipalmitoylphosphatidylcholine), cholesterol, DSPE-mPEG2000 and songolin in the liposome is the molar ratio of the dosage in the liposome preparation process.

[0009] In some embodiments, the phospholipid is any one or more of DPPC, soybean lecithin, and egg yolk lecithin.

[0010] In some embodiments, the drug loading of the Songguoling nanoliposomes is 7.24%±2%.

[0011] In some embodiments, the Songguoling nanoliposomes are spherical with an average diameter of 102±5 nm.

[0012] In some embodiments, the zeta potential of the Songguoling nanoliposomes is -15±2 mV.

[0013] According to another aspect of the present invention, there is provided a method for preparing Songguoling nanoliposomes, comprising the following steps:

[0014] S1. Dissolve phospholipids, cholesterol, DSPE-mPEG2000 and Songguoling in a solvent, and remove the solvent by rotary evaporation to form a film;

[0015] S2. Add an aqueous medium to the film formed in step S1 to fully hydrate the film and let it fall off to obtain a suspension, and perform ultrasonic dispersion on the suspension with an ultrasonic power of 10% to 30%. After the ultrasonic dispersion is completed, Songguoling nanoliposomes can be obtained.

[0016] The preparation method of the Songguoling nanoliposome in the present invention is a thin film hydration-ultrasonic dispersion method.

[0017] It should be noted that the general preparation process of liposomes is: after the film material is formed, an aqueous medium containing the core material is added to hydrate the film. However, in the present invention, Songguoling is a fat-soluble drug that is difficult to dissolve in water, so it is dissolved together with the film material, and the core material is coated while the film material is formed, and finally the organic solvent is removed, and the encapsulation rate is high. If the original drug core material is added after the film material is formed, the drug cannot be fully dissolved, and the drug loading rate and encapsulation rate will decrease.

[0018] In some embodiments, in step S1, phospholipids, cholesterol and DSPE-mPEG2000 are first dissolved in a solvent, and then the solvent is used to dissolve songguoling and then added to the reaction system.

[0019] In some embodiments, the secondary emulsification method, ethanol injection method or reverse evaporation method can also be selected to prepare the Songguoling nanoliposomes in the present invention.

[0020] In some embodiments, the method of removing the solvent by rotary evaporation to form a thin film in step S1 is to perform rotary evaporation at 230 mbar until the solvent is completely evaporated.

[0021] In some embodiments, step S1 is: add phospholipids, cholesterol and DSPE-mPEG2000 to a 500 mL round-bottom flask, add 4 mL of chloroform to fully dissolve them, dissolve songguoling with 1 mL of chloroform and add it to the round-bottom flask, mix well and perform rotary evaporation at 230 mbar until the chloroform is completely evaporated to form a thin film on the wall of the round-bottom flask.

[0022] In some embodiments, the aqueous medium in step S2 is PBS buffer.

[0023] In some embodiments, the temperature for fully hydrating and shedding the film in step S2 is 60°C.

[0024] In some embodiments, step S2 allows the film to be fully hydrated and detached under stirring conditions, and the stirring speed is 300 rpm.

[0025] In some embodiments, the time required for the film to be fully hydrated and detached in step S2 is 30 minutes.

[0026] In some embodiments, the ultrasonic dispersion operation in step S2 is specifically as follows: placing the suspension obtained by hydration and shedding of the thin film on ice for ultrasonication, with an ultrasonic power of 10% to 30% (i.e., 10% to 30% of the maximum power of the instrument), and an ultrasonic mode of 15 seconds per ultrasonication, pausing for 15 seconds, and ending the ultrasonication after a cycle of 30 minutes.

[0027] The purpose of the ultrasonic dispersion is to improve the uniformity of the particle size of the obtained liposomes, thereby improving their stability. In the process of preparing liposomes, if the particle size is uneven, it will affect the quality of the liposomes and subsequent experimental results. It should be noted that, since the ultrasonic power of the present invention is relatively small and the time is relatively short, and the operation is strictly on ice, the damage to the liposome components by the ultrasonic operation is greatly reduced.

[0028] In some embodiments, step S2 further includes filtering, ultrafiltration and volume fixing steps after ultrasonic dispersion.

[0029] In some embodiments, the filtration is as follows: collecting the suspension after ultrasonic dispersion, filtering and collecting with a 0.22 μm filter, and taking the filtrate.

[0030] In some embodiments, the ultrafiltration is as follows: the filtrate is transferred to an ultrafiltration tube and centrifuged at 3000 rpm for 1 hour. The purpose of this ultrafiltration step is to remove liposomes that do not encapsulate the songolin and free songolin monomers.

[0031] In some embodiments, the above-mentioned volume adjustment is: using PBS buffer to adjust the volume of the Songguoling nanoliposomes in the ultrafiltration tube to 3 mL for use.

[0032] In some embodiments, step S2 is: add 5 mL of PBS buffer to the round-bottom flask of step S1, put it into a rotor, and stir it at 300 rpm and 60°C for 30 minutes. During this period, the flask can be manually rotated to allow the PBS buffer to fully infiltrate the thin film on the wall of the flask; after 30 minutes, a suspension formed by hydration and shedding of the thin film is obtained, and it is placed on ice for ultrasonication. The ultrasonic power is 20%, and the ultrasonic mode is 15 seconds per ultrasonication, paused for 15 seconds, and the ultrasonication is ended after a cycle of 30 minutes; the suspension after ultrasonic dispersion is collected, filtered and collected with a 0.22 μm filter, and the filtrate is taken; the filtrate is transferred to an ultrafiltration tube and centrifuged at a speed of 3000 rpm for 1 hour, and the volume of the Songguoling nanoliposomes in the ultrafiltration tube is fixed to 3 mL using PBS buffer for standby use.

[0033] According to another aspect of the present invention, there is provided the use of Songguoling nanoliposomes in the preparation of a drug for treating acute lung injury.

[0034] In some embodiments, the drug for treating acute lung injury is administered by aerosol inhalation.

[0035] According to another aspect of the present invention, there is provided the use of Songguoling nanoliposomes in the preparation of pulmonary anti-inflammatory drugs.

[0036] The Songguoling nanoliposomes provided by the present invention can reduce the levels of inflammatory factors such as TNF-α, IL-6, IL-1β and the like in lung tissue and relieve inflammation of lung tissue, and therefore have good application prospects in the preparation of lung anti-inflammatory drugs.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] The songguoling nanoliposomes provided by the present invention have good biosafety and compatibility, and can act on the lungs in a targeted manner, reduce the expression levels of inflammatory factors such as IL-6, IL-1β and TNF-α in mice, and relieve inflammation; at the same time, they can increase the expression levels of proteins such as ZO-1, VE-Cadherin and Claudin5, alleviate damage to the lung barrier, and achieve the treatment of mice with acute lung injury, and the treatment effect is significantly better than that of free songguoling monomers. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The particle size distribution diagram of Son-Lipo obtained in Example 1 of the present invention and the Zeta potential data diagram of Son-Lipo and Lipo obtained in Comparative Example 1 are shown.

[0040] Figure 2 This is a transmission electron microscope image of Son-Lipo obtained in Example 1 of the present invention.

[0041] Figure 3 This is a graph showing the hemolytic test results of Son-Lipo and Songorine monomers obtained in Example 1 of the present invention.

[0042] Figure 4 This is a graph showing the effects of different concentrations of different groups of the present invention on the viability of RAW264.7 cells and HUVEC cells.

[0043] Figure 5 This is a graph showing the effects of different groups of the present invention on the mRNA of proinflammatory factors IL-6, IL-1β and TNF-α in RAW264.7 cells intervened by LPS.

[0044] Figure 6 This is a graph showing the effects of different groups of the present invention on the fluorescence intensity of ZO-1, a lung barrier function indicator of HUVEC cells intervened by LPS.

[0045] Figure 7 This is a graph showing the effects of different groups of the present invention on the protein expression of ZO-1, a lung barrier function indicator of HUVEC cells intervened by LPS.

[0046] Figure 8 This is a graph showing the effects of different groups of the present invention on the total cell number and total protein concentration in the bronchoalveolar lavage fluid of LPS-intervention mice.

[0047] Fig. 9 This is a graph showing the effects of different groups of the present invention on pathological damage to the lung tissue of mice treated with LPS.

[0048] Fig.10 This is a graph showing the effects of different groups of the present invention on the pro-inflammatory factors IL-6, IL-1β, TNF-α, and iNOS mRNA in mice treated with LPS.

[0049] Fig.11 This is a graph showing the immunohistochemical changes in the mouse lung barrier indicator ZO-1 in different groups of the present invention.

[0050] Fig.12 This is a graph showing the effects of different groups of the present invention on the mRNA expressions of mouse lung barrier indicators ZO-1, VE-Cadherin and Claudin5.

[0051] Fig.13 This is a study on the cardio-liver-spleen-kidney toxicity of different groups in the LPS-induced acute lung injury mouse model. DETAILED DESCRIPTION

[0052] The present invention is further described in detail below in conjunction with the examples and drawings, but the implementation of the present invention is not limited thereto. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from the market unless otherwise specified, among which the chemical structure of Songorine is as follows:

[0053]

[0054] In the present invention, the compound is provided by Chengdu Purifa Technology Co., Ltd., and the purity is measured by HPLC-DAD peak area normalization method to be above 98%. Songguoling is dissolved in dimethyl sulfoxide (DMSO), a certain amount is mixed and diluted with PBS to the required concentration. The DMSO content in the final solution of Songguoling is less than or equal to 1%.

[0055] Example 1

[0056] A method for preparing Songguoling nanoliposomes comprises the following steps:

[0057] S1. DPPC, cholesterol and DSPE-mPEG2000 were added into a 500 mL round-bottom flask at a mass of 40.18 mg, 5.49 mg and 4.27 mg, respectively. After fully dissolving in 4 mL of chloroform, 4 mg of sungorin was dissolved in 1 mL of chloroform and added into the round-bottom flask. After mixing, the mixture was rotary evaporated at 230 mbar until the chloroform was completely evaporated to form a thin film on the wall of the round-bottom flask.

[0058] S2. Add 5 mL of PBS buffer to the round-bottom flask of step S1, put it in a rotor, and stir it at 300 rpm and 60°C for 30 min. During this period, the flask can be manually rotated to allow the PBS buffer to fully infiltrate the thin film on the wall of the flask; after 30 min, a suspension formed by hydration and shedding of the thin film is obtained, and it is placed on ice for ultrasonication with an ultrasonic power of 20%. The ultrasonication mode is 15 s per ultrasonication, 15 s pause, and the ultrasonication is terminated after a cycle of 30 min; the suspension after ultrasonic dispersion is collected, filtered and collected using a 0.22 μm filter, and the filtrate is taken; the filtrate is transferred to an ultrafiltration tube and centrifuged at a speed of 3000 rpm for 1 h, and the volume of the Songguoling nanoliposomes in the ultrafiltration tube is fixed to 3 mL using PBS buffer for standby use.

[0059] The Songguoling nanoliposomes obtained in this example are denoted as Son-Lipo, which include a core material and a membrane material. The core material is Songguoling, and the membrane material is prepared from DPPC, cholesterol and DSPE-mPEG2000; the molar ratio of each component in the liposome is Songguoling: DPPC: cholesterol: DSPE-mPEG2000 = 14:77:20:3.

[0060] The Songguoling nanoliposomes obtained in this example were characterized, and it was found that the drug loading of the Songguoling nanoliposomes was 7.24%, and the encapsulation efficiency of Songguoling was 75.03%; the Songguoling nanoliposomes were spherical with an average diameter of 101.77 nm. Figures 1-2 As shown; the Zeta potential of Songguoling nanoliposomes is -14.64mV. Figure 1 shown.

[0061] The method for determining the drug loading of Songguoling nanoliposomes in this embodiment comprises the following steps:

[0062] The Songguoling nanoliposome solution obtained by the fixed volume in step S2 is diluted in the organic solvent acetonitrile at a ratio of 1 / 10, and after ultrasonic disruption for 1 hour, it is collected and centrifuged at 12000 rpm for 10 minutes, and then filtered and collected with a 0.22 μm organic filter. Then, the highest absorption peak of the drug is detected by an ultraviolet spectrophotometer, the optimal absorption wavelength and the OD value of the drug are determined, and the drug loading of the liposome drug is calculated based on the standard curve.

[0063] Comparative Example 1

[0064] A nanoliposome, denoted as Lipo, includes only a membrane material, which is prepared from DPPC, cholesterol and DSPE-mPEG2000, wherein the molar ratio of each component is DPPC: cholesterol: DSPE-mPEG2000 = 77:20:3;

[0065] The nanoliposomes in this comparative example are spherical, with a diameter in the range of 80.43 to 83.18 nm and a Zeta potential of -11.85 mV.

[0066] The preparation method of nanoliposomes in this comparative example is carried out according to that in Example 1, wherein the only difference from Example 1 is that:

[0067] Songguoling is not added in step S1.

[0068] The liposomes obtained in Example 1 and Comparative Example 1 were characterized, and the experimental results are as follows: Figure 1 As shown: Zeta potential shows that Son-lipo is negatively charged with an average potential of -14.64mV, while the average Zeta potential of Lipo is -11.85mV. Transmission electron microscopy observations show that Son-lipo has a uniform spherical morphology with a diameter in the range of 100-105nm, while the diameter of Lipo is in the range of 80.43-83.18nm, which is consistent with the results measured by DLS.

[0069] Experimental study on the pharmacological effects of Songguoling nanoliposomes

[0070] Next, cell and animal experiments were conducted using the Songorine nanoliposomes Son-Lipo prepared in Example 1, the nanoliposomes Lipo in Comparative Example 1, and free Songorine monomers to explore their pharmacological effects.

[0071] 1. Cell experiments and related index determination

[0072] 1. Biosafety Assessment

[0073] 1) Hemolysis test

[0074] The compatibility of Songorine and Son-lipo with red blood cells was tested by hemolysis test. First, 2 mL of fresh blood from rat orbit was taken and 10 mL of 1×10 4Unit sodium heparin PBS buffer. The diluted blood was centrifuged at 3000rpm for 10min to separate the red blood cells, washed 3 times until the supernatant was blood-free, and finally diluted with PBS buffer to a 2% cell suspension. 500μL of diluted red blood cells and 500μL of different concentrations of Songorine or Son-lipo were added to a 1.5mL centrifuge tube and incubated at 37℃ for 3h. Ultrapure water and PBS buffer were used to directly contact the diluted red blood cells as positive control and negative control, respectively. Finally, all tubes were centrifuged (1000rpm, 15min) to separate the supernatant, and the absorption was measured at 540nm with an enzyme reader. The hemolysis rate calculation formula is (Ap-Ab) / (At-Ab)×100%, where Ap is the drug absorbance value, At is the positive control group, and Ab is the negative control group.

[0075] The results of hemolysis test were as follows Figure 3 As shown, Son-Lipo provided in Example 1 of the present invention is incompatible with blood and has good biocompatibility.

[0076] 2) Cell Counting Kit-8 (CCK-8) toxicity test

[0077] CCK8 toxicity experiments were performed using RAW264.7 macrophages and human umbilical vein endothelial cells (HUVEC). RAW264.7 and HUVEC were cultured in high-glucose DMEM medium containing 10% goat bovine serum and 1% penicillin-streptomycin solution, supplemented with 5% CO 2 , cultured at 37°C. CCK-8 kit (GLPBIO, GK10001-5) was used to detect the cytotoxicity of the drug. RAW264.7 cells and HUVEC cells were cultured at 1×10 4 and 5×10 3 The cells were seeded at a density of 100 μL in a 96-well culture plate. After 24 h, the control group was treated with fresh DMEM medium only, and the other groups were treated with 100 μL of fresh DMEM medium containing different concentrations of Lipo, Songorine, or Son-lipo. After 24 h of treatment, 10 μL of CCK-8 solution was diluted in 100 μL of fresh complete medium; then the cells were incubated with the diluted CCK-8 solution for 2 h. Finally, the absorbance of each well was measured at 450 nm using a microplate reader.

[0078] The results of CCK8 toxicity experiment are as follows Figure 4 As shown, the Son-lipo provided in Example 1 of the present invention has little effect on cell viability and has good biosafety.

[0079] 2. Anti-inflammatory effect study

[0080] The cell culture technique was the same as that of the CCK8 toxicity experiment. RAW264.7 cells were inoculated in 6-well plates and grown to 60%-70% confluence, and then incubated with 2 mL of fresh serum-free medium containing 250 μmol / L Lipo, Songorine or Son-lipo for 10-12 h. The Control and Model groups were incubated with only 2 mL of fresh serum-free medium for 10-12 h. Subsequently, except for the Control group, the other groups were stimulated with 500 ng / mL LPS in 2 mL of serum-free medium for 4 h. The drug-treated groups were incubated again with an equal amount of Lipo, Songorine or Son-lipo for 6 h, and the Model group was incubated with 2 mL of fresh serum-free medium for 6 h. Finally, the cells were collected and the levels of TNF-α, IL-6, and IL-1β inflammatory factors were determined by qRT-PCR. The primer sequences were:

[0081] TNF-aF:TTGTCTACTCCCAGGTTCTCT;

[0082] TNF-aR:GAGGTTGACTTTCTCCTGGTATG;

[0083] IL-6-F:CTTCCATCCAGTTGCCTTCT;

[0084] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;

[0085] IL-1β-F:GGTGTGGTGACGTTCCCATTA;

[0086] IL-1β-R:ATTGAGGTGGAGAGCTTTCAG;

[0087] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0088] Tubulin-R:TCGGAGATGCGCTTGAATAG.

[0089] Figure 5 The results showed that the Son-lipo of the present invention can significantly down-regulate the mRNA content of pro-inflammatory factors TNF-α, IL-6, and IL-1β in RAW264.7 cells, and Songorine monomer also has a certain down-regulating effect on the mRNA content of pro-inflammatory factors, while the mRNA content of these pro-inflammatory factors originally showed an upward trend after being stimulated by LPS. This shows that Songorine and Son-lipo have good anti-inflammatory effects on the LPS-induced RAW264.7 inflammatory cell model, and the effect of Songorine nanoliposome Son-lipo is significantly better than that of the monomer.

[0090] 3. Effect of Son-lipo on ZO-1, a lung barrier function marker in HUVEC cells treated with LPS

[0091] 1) Effect of Son-lipo on the fluorescence intensity of ZO-1, a lung barrier function indicator in HUVEC cells treated with LPS

[0092] HUVEC cells were inoculated to 100% confluence in 0.17 mm glass-bottomed culture dishes, and then 1 μg / mL LPS was used to intervene the cells. The control group did not receive LPS intervention. In the treatment group, Songorine, Son-lipo, and an equal volume of Lipo were added to the culture dishes, respectively, so that the concentration in the culture dishes was 250 μmol / L. The control group and the model group did not add any drugs. After 24 hours, fluorescent staining was performed, in which the dilution ratio of the tight junction factor ZO-1 antibody was 1:1000 (21773-1-AP), and the dilution ratio of the donkey anti-rabbit Cy3 antibody was 1:200 (205302, Biolend), and finally a confocal microscope was used to take pictures.

[0093] Figure 6 The results showed that compared with the Control group, the expression of tight junction protein ZO-1 in the Model group was significantly reduced, and the tight junction structure between cells was severely damaged, while compared with the Model group, the expression of ZO-1 in the Son-lipo group was significantly increased. This shows that the Son-lipo of the present invention can significantly improve the damage of the lung barrier of HUVEC cells caused by LPS.

[0094] 2) Effect of Son-lipo on the protein expression of ZO-1, a lung barrier function indicator, in HUVEC cells treated with LPS

[0095] HUVEC were seeded in 6-well plates to 100% confluence. Except for the Control group, 1 μg / mL LPS was added to stimulate the cells. The treatment groups were treated with 250 μmol / L Songorine, Son-lipo and Lipo respectively. The Control group and the Model group did not add any drugs, but only added solvent. The cells were collected after 12 hours. RIPA lysis buffer, PMSF and phosphatase inhibitor were mixed in a volume ratio of 100:1:1, added to the cells, shaken on ice for 2 hours, centrifuged at 4°C and 12000rpm for 10 minutes, and the supernatant was collected and the protein concentration was measured using a BCA kit (Biyuntian, P0010S). The cell protein sample with the measured concentration was added with 5×SDS-PAGE protein loading buffer and boiled at 95°C for 7 minutes, then loaded onto the pre-prepared gel for SDS-PAGE electrophoresis separation, 80V30min, 120V 1.5h, and transferred to the membrane at 300mA after the electrophoresis. After the transfer, the membrane was transferred to a 5% skim milk powder culture dish and blocked on a shaker for 1-2 hours, and then incubated with ZO-1 antibody at 4°C overnight. After that, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. Finally, the protein bands on the membrane were imaged using a chemiluminescence imaging system.

[0096] Figure 7 The results showed that the protein bands of HUVEC cells stimulated by LPS were expressed less than those of the Control group, while the intensity of the protein bands increased significantly after Son-lipo treatment, indicating from the protein level that Son-lipo of the present invention can improve the damage to the barrier function of HUVEC cells caused by LPS.

[0097] 2. Animal experiments and related index determination

[0098] 1. Animal experiment grouping, modeling and drug administration: After anesthetizing mice in the control group, mice were injected with 5 mg / kg of PBS into the trachea. After anesthetizing mice in the treatment group, mice were injected with 5 mg / kg of LPS into the trachea. The acute lung injury model was induced on day 0. The inhalation drug was administered once 2 hours after the modeling, and the second time after 12 hours. Lung function was tested and samples were collected 24 hours later. Starting from the modeling, the drug was administered by inhalation twice a day (once every 12 hours) for 3 consecutive days. Three days after infection, the mice were killed by dislocating the neck after blood was collected from the eyeballs. The dosage of each group of mice is as follows:

[0099] Songorine group: Mice inhaled Songorine twice a day at a concentration of 250 μmol / L and a dosing volume of 6 mL / time.

[0100] Son-Lipo group: Mice inhaled Son-Lipo twice a day at a concentration of 250 μmol / L and a dosing volume of 6 mL / time.

[0101] Lipo group: Mice inhaled Lipo twice a day at a concentration of 250 μmol / L and a dosing volume of 6 mL / time.

[0102] Control group: Mice inhaled PBS twice a day, with a dosing volume of 6 mL / time.

[0103] Model group: Mice inhaled PBS twice a day, with a dosing volume of 6 mL / time.

[0104] 2. Determination of relevant indicators

[0105] 1). Effects of Son-lipo on the total cell number and total protein concentration in bronchoalveolar lavage fluid of LPS-treated mice

[0106] After the mice were killed, their limbs were fixed, and a catheter was inserted into the mouse trachea through a small incision in the neck and fixed. The mice were irrigated with pre-cooled sterile saline or PBS, with 0.7 mL aspirated each time, and repeated three times. The collected irrigating fluid was centrifuged at 4°C and 3000 rpm for 10 min to detect total protein concentration and total cell count.

[0107] Figure 8 The results showed that Son-lipo of the present invention enhanced the permeability of mouse lungs and significantly reduced the total cell count and total protein concentration in the bronchoalveolar lavage fluid of mice with acute lung injury model.

[0108] 2). Effect of Son-lipo on pathological damage of lung tissue in mice treated with LPS

[0109] Fresh lung tissue was fixed in 4% paraformaldehyde solution for 24 hours, then embedded in paraffin and sliced ​​to a thickness of 4 μm. The slides were picked up and dried, and stained with hematoxylin and eosin according to the procedure. The stained slides were dried, sealed, and finally photographed under an optical microscope.

[0110] Fig. 9 The results showed that in the LPS intervention mouse experiment, the model group had obvious neutrophil infiltration in the lung tissue, thickening of the alveolar wall, and obvious destruction of the normal lung structure. Son-lipo treatment can effectively improve the above damage.

[0111] 3). Effects of Son-lipo on pro-inflammatory factors IL-6, IL-1β, TNF-α, and iNOS mRNA in lung tissue of LPS model mice

[0112] Total RNA was extracted from lung tissue, and the housekeeping gene α-Tubulin was selected as the internal reference gene. -ΔΔCTMethods The relative normalized mRNA expression of genes was calculated, and the expression of inflammatory factors (TNF-α, IL-6, IL-1β, iNOS) was determined. The primer sequences were:

[0113] TNF-aF:TTGTCTACTCCCAGGTTCTCT;

[0114] TNF-aR:GAGGTTGACTTTCTCCTGGTATG;

[0115] IL-6-F:CTTCCATCCAGTTGCCTTCT;

[0116] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;

[0117] IL-1β-F:GGTGTGGTGACGTTCCCATTA;

[0118] IL-1β-R:ATTGAGGTGGAGAGCTTTCAG;

[0119] iNOS-F:GGAATCTTGGAGCGAGTTGT;

[0120] iNOS-R:CCTCTTGTCTTTGACCCAGTAG;

[0121] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0122] Tubulin-R:TCGGAGATGCGCTTGAATAG.

[0123] Fig.10 The results showed that Son-lipo of the present invention can effectively inhibit the levels of inflammatory factors TNF-α, IL-6, IL-1β, and iNOS in the LPS-induced acute lung injury mouse model, and the effect of Son-lipo is better than Songorine.

[0124] 4). Son-lipo on the immunohistochemical changes of lung barrier marker ZO-1

[0125] After paraffin sections of lung tissue were sliced, they were routinely dewaxed and dehydrated, and then rinsed with PBS for 5 min × 3 times. The sections were placed in citrate buffer (PH = 6.0) and heated at high temperature for 15 min, maintained at low temperature for 10 min, and then naturally cooled for about 120 min, and rinsed with PBS for 5 min × 3 times. 3% H 2 O 2Incubate at room temperature for 15 minutes to eliminate the activity of endogenous peroxidase, rinse with PBS, 5 minutes × 3 times. Block with 5% normal goat serum and incubate at room temperature for 30 minutes. Add primary antibody (primary antibody dilution concentration is 1:2000), incubate overnight at 4°C. After washing with PBS, add secondary antibody, leave at room temperature for 2 hours, rinse with PBS 3 times, perform DAB color development at room temperature, control the reaction speed under the microscope, color development for 4-5 minutes, and rinse with distilled water to stop color development. Lightly counterstain with hematoxylin for 5 minutes, rinse with tap water for 5 minutes, dehydrate with gradient alcohol upward, seal with neutral gum, and observe under a microscope.

[0126] Fig.11 The results showed that ZO-1 was expressed in large quantities in the cytoplasm of alveolar cells of normal Control group mice, while the expression level of ZO-1 in LPS-induced acute lung injury model group was significantly lower than that in normal Control group and Son-lipo group, indicating that the content of this important protein that constitutes the alveolar permeability barrier is reduced during lung injury, directly destroying its integrity, while Son-lipo can repair the alveolar barrier function and maintain its integrity.

[0127] 5). Effect of Son-lipo on the mRNA expression of pulmonary endothelial barrier markers ZO-1, VE-Cadherin and Claudin5

[0128] According to the instructions of RNA extraction kit (Tiangen Biochemical, DP419), lung tissue was used to extract total RNA using Trizol reagent, the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using PrimeScript RT kit and gDNAEraserPerfect Real Time (purchased from Takara Bio). Using the cDNA of each sample as a template, qRT-PCR amplification detection and analysis of the mRNA expression of each target gene (ZO-1, VE-Cadherin, and Claudin5) was performed according to 2 -ΔΔCT Methods The relative normalized mRNA expression of genes was calculated, and the primer sequences were:

[0129] ZO-1-F:ACTCCCACTTCCCCAAAAAC;

[0130] ZO-1-R:CCACAGCTGAAGGACTCACA;

[0131] VE-Cadherin-F:ACTCCCACTTCCCCAAAAAC;

[0132] VE-Cadherin-R:CCACAGCTGAAGGACTCACA;

[0133] Claudin5-F:ACTGCCTTCCTGGACCACAAC;

[0134] Claudin5-R:CGCCAGCACAGATTCATACACCT;

[0135] Actin-F:CCTGGCACCCAGCACAAT;

[0136] Actin-R:GGGCCGGACTCGTCATAC.

[0137] Fig.12 The results showed that compared with the model group, Son-lipo of the present invention significantly improved the lung barrier function of mice.

[0138] 6). Study on the toxicity of Songorine and Son-lipo to the heart, liver, spleen and kidney in LPS-induced acute lung injury mouse model

[0139] Mouse histopathology was evaluated by hematoxylin-eosin (HE) staining. Fresh hearts, livers, kidneys, and spleens were fixed with 4% paraformaldehyde for at least 24 hours, then embedded in paraffin and cut into 4 μm thick serial sections. The sections were flattened on glass slides, then stained with HE, dehydrated, and mounted. The slides were imaged using a 100x magnifying glass.

[0140] Fig.13 The results showed that Songorine and Son-lipo of the present invention had no obvious toxicity to the heart, liver, spleen and kidney of the acute lung injury mouse model.

[0141] In other embodiments, the preparation parameters or raw material ratios can be changed based on Example 1, for example, the molar ratio of succinate, phospholipid, cholesterol and DSPE-mPEG2000 can be 10:80:18:3, 10:75:18:3, 18:75:22:3, 18:80:22:3, 18:75:18:3, 10:75:22:3, etc.

[0142] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. A Songguoling nanoliposome, comprising a core material and a membrane material, characterized in that: The core material is songguoling, and the membrane material is mainly prepared from phospholipids, cholesterol and DSPE-mPEG2000; the molar ratio of songguoling, phospholipids, cholesterol and DSPE-mPEG2000 is (10-18): (75-80): (18-22): 3, and the encapsulation rate of the songguoling nanoliposome is 75.03%±0.5%.

2. The Songguoling nanoliposome according to claim 1, characterized in that The phospholipids are any one or more of DPPC, soybean lecithin, and egg yolk lecithin.

3. The Songguoling nanoliposome according to claim 1, characterized in that The drug loading of the Songguoling nanoliposome is 7.24%±2%.

4. The Songguoling nanoliposome according to claim 1, characterized in that: The Songguoling nanoliposomes are spherical, with an average diameter of 102±5 nm.

5. The Songguoling nanoliposome according to claim 1, characterized in that: The Zeta potential of the Songguoling nanoliposome is -15±2mV.

6. The method for preparing the Songguoling nanoliposome according to any one of claims 1 to 5, characterized in that: The steps include: S1. Dissolve phospholipids, cholesterol, DSPE-mPEG2000 and Songguoling in a solvent, and remove the solvent by rotary evaporation to form a film; S2. Add an aqueous medium to the film formed in step S1 to fully hydrate the film and let it fall off to obtain a suspension, and perform ultrasonic dispersion on the suspension with an ultrasonic power of 10% to 30%. After the ultrasonic dispersion is completed, Songguoling nanoliposomes can be obtained.

7. Use of the Songguoling nanoliposomes according to any one of claims 1 to 5 in the preparation of a drug for treating acute lung injury.

8. The use according to claim 7, characterized in that: The administration method of the drug for treating acute lung injury is aerosol inhalation administration.

9. Use of the Songguoling nanoliposomes according to any one of claims 1 to 5 in the preparation of pulmonary anti-inflammatory drugs.

Citation Information

Patent Citations

  • Corosolic acid liposome as well as preparation method and application thereof

    CN110548006A

  • Application of tripterine liposome in preparation of medicine for preventing and treating acute respiratory distress syndrome

    CN116196278A

  • Aerosol inhalation nano-liposome composition for treating pulmonary fibrosis as well as preparation method and application of aerosol inhalation nano-liposome composition

    CN118236357A